Send us a text

Summary:  The medical term is vasomotor symptoms (VMS); the more common term is hot flashes and night sweats; the term used by my wife is Sweaty Betty.  And that’s as nice as she can be about it.  Recently the FDA issued a Priority Review for Veozah, due to its unique non-hormonal action and if approved, the potential significant improvements it might provide for moderate to severe hot flashes, compared to standard applications.  This May it was approved.  In this episode we introduce Veozah as a new option in the treatment of hot flashes, this discussion as always including the Risk-Benefit analysis of the drug. 

Topics:

·      Veozah 01:21

·      FDA Priority Review 01:43

·      Risk-Benefit 02:13

·      VMS (Vasomotor Symptoms) 03:55

·      Hypothalamus 05:27

·      Thermoregulatory Dysfunction 05:41

·      Biofeedback 05:57

·      Hormonal Therapy (Estrogen/Progesterone) 06:39

·      Non-Hormonal Therapy 07:29
      (antidepressants, gabapentin, pregabalin, oxybutynin, clonidine and Veozah)       

·      Mind-Body Options 08:15

·      Veozah Mechanism of Action 09:25

·      Randomized, Placebo-Controlled, Double Blind Study 10:00

·      Placebo Effect 10:41

·      Risk-Benefit Analysis 12:20

·      Risk-Benefit Analysis of Veozah 13:10

·      Veozah Possible Side Effects 14:10

·      Veozah Drug-Drug Interactions 15:40

·      Post Marketing Data 16:30

·      Monitor-Monitor-Monitor 17:15

·      Veozah Cost 18:00

Questions and comments to [email protected]